Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2017 07:00 ET | Source: Cyclacel

Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

BERKELEY HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
August 02, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
July 21, 2017 14:00 ET | Source: Cyclacel

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...
July 19, 2017 08:30 ET | Source: Cyclacel

Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering

BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...
May 11, 2017 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., May 11, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...
May 05, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results

BERKELEY HEIGHTS, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
April 04, 2017 13:00 ET | Source: Cyclacel

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

- Preclinical Data Presented at the AACR 2017 Meeting - BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the...
April 02, 2017 13:00 ET | Source: Cyclacel

Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

BERKELEY HEIGHTS, N.J., April 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation by independent...
March 28, 2017 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

BERKELEY HEIGHTS, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...
March 21, 2017 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

BERKELEY HEIGHTS, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...